# oncology

About 10 search results

Sort by Date

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

Pantai Hospital Kuala Lumpur Launches AI-Powered Adaptive Radiotherapy System to Advance Personalised Cancer Care in Malaysia

Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration

Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

About Storm Media

The Storm Media (world.storm.mg) is dedicated to bringing Taiwan's voice to the world. We deliver timely, balanced, and internationally oriented reporting and in-depth analysis on key issues including democratic politics, cross-strait relations, geopolitics, Indo-Pacific strategy, technology industry, and economic trends — helping global readers gain a deeper understanding of Taiwan and the Asia-Pacific region.

The Storm Media (Chinese)

The Storm Media Japan

The Journalist

1% STYLE

Neihu District, Ruiguang Road, Lane 513, No. 37, 4F. Taipei, 114.

Stay True・Look Beyond

Version: 20260616-090240